Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 13/20 | 0.68 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.54 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HRH1 | P35367 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL613112 | 0.85 | NOTUM (0.81) | NOTUMALDH1A1SMN1; SMN2 | |
| SCHEMBL4961935 | 0.85 | NOTUM (0.81) | NOTUMALDH1A1SMN1; SMN2 | |
| SCHEMBL16695597 | 0.81 | NOTUM (1.00) | NOTUM | |
| SCHEMBL892785 | 0.81 | NOTUM (1.00) | NOTUM | |
| SCHEMBL27615103 | 0.77 | S1PR5 (0.57) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL17127953 | 0.77 | MBTD1 (0.61) | MBTD1L3MBTL3L3MBTL1ALDH1A1HDAC4 | |
| SCHEMBL12663092 | 0.77 | MBTD1 (0.61) | MBTD1L3MBTL3L3MBTL1ALDH1A1HDAC4 | |
| SCHEMBL5007409 | 0.75 | AKR1C3 (0.51) | NOTUMALDH1A1HTR2AHRH1HTR2C | |
| SCHEMBL6373468 | 0.75 | CYP2D6 (0.59) | ALDH1A1HTR2AHRH1HTR2CHTR2B | |
| SCHEMBL13609480 | 0.75 | SMN1; SMN2 (0.58) | MBTD1L3MBTL3L3MBTL1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | XDH, CYP2D6, F12 | NOTUM 3794/4885MBTD1 4035/4885L3MBTL3 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.